Introduction: Sodium chloride supplementation in salt-wasting congenital adrenal hyperplasia (CAH) is generally recommended in infants, but its implementation in routine care is very heterogeneous. Objective: To evaluate oral sodium chloride supplementation, growth, and hydrocortisone and fludrocortisone dose in infants with salt-wasting CAH due to 21-hydroxylase in 311 infants from the AQUAPE CAH database. Results: Of 358 patients with classic CAH born between 1999 and 2015, 311 patients had salt-wasting CAH (133 females, 178 males). Of these, 86 patients (27.7%) received oral sodium chloride supplementation in a mean dose of 0.9 ± 1.4 mmol/kg/day (excluding nutritional sodium content) during the first year of life. 225 patients (72.3%) were not treated with sodium chloride. The percentage of sodium chloride-supplemented patients rose from 15.2% in children born 1999–2004 to 37.5% in children born 2011–2015. Sodium chloride-supplemented and -unsupplemented infants did not significantly differ in hydrocortisone and fludrocortisone dose, target height-corrected height-SDS, and BMI-SDS during the first 2 years of life. Conclusion: In the AQUAPE CAH database, approximately one-third of infants with salt-wasting CAH receive sodium chloride supplementation. Sodium chloride supplementation is performed more frequently in recent years. However, salt supplementation had no influence on growth, daily fludrocortisone and hydrocortisone dose, and frequency of adrenal crisis.

Keywords:
Congenital adrenal hyperplasia, Salt-wasting congenital adrenal hyperplasia, Sodium chloride supplementation, Hydrocortisone, Fludrocortisone
1.
Speiser PW, White PC: Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776–788.
2.
Hughes IA: Congenital adrenal hyperplasia – a continuum of disorders. Lancet 1998; 352: 752–754.
3.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC, Endocrine Society: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 4133–4160.
4.
Mullis PE, Hindmarsh PC, Brook CG: Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency. Eur J Pediatr 1990; 150: 22–25.
5.
Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiß HC, Hesse V, von Hippel A, Jaeger U, Johnson D, Korte W, Menner K, Müller G, Müller JM, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen HU, Zabransky S, Zellner K, Ziegler A, Hebebrand J: Percentiles of body mass index in children and adolescents evaluated from different regional German studies (in German). Monatsschr Kinderheilkd 2001; 149: 807–818.
6.
Neuhauser H, Schienkiewitz A, Schaffrath Rosario A, Dortschy R, Kurth BM: Referenzperzentile für anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS). 2013, Robert Koch-Institut, Berlin, RKI-Hausdruckerei, Berlin (ISBN 978-3-89606-218-5).
7.
Flynn JT: Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14: 332–341.
8.
Bizzarri C, Pedicelli S, Cappa M, Cianfarani S: Water balance and “salt wasting” in the first year of life: the role of aldosterone-signaling defects. Horm Res Paediatr 2016; 86: 143–153.
9.
Martinerie L, Pussard E, Foix-L’Hélias L, Petit F, Cosson C, Boileau P, et al: Physiological partial aldosterone resistance in human newborns. Pediatric Research 2009; 66: 323–328.
10.
Bonfig W, Schwarz HP: Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age. Clin Endocrinol 2014; 81: 871–875.
11.
Bonfig W, Schmidt H, Schwarz HP: Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr 2011; 75: 32–37.
12.
Kawano A, Kohno H, Miyako K: A retrospective analysis of the growth pattern in patients with salt-wasting 21-hydroxylase deficiency. Clin Pediatr Endocrinol 2014; 23: 27–34.
13.
Van der Kamp HJ, Otten BJ, Buitenweg N, De Muinck Keizer-Schrama SMPF, Oostdijk W, Jansen M, Delemarre-de Waal HA, Vulsma T, Wit JM: Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child 2002; 87: 139–144.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.